Please ensure Javascript is enabled for purposes of website accessibility

Chemours Company Spikes 14% on Major EPS Improvement, but There's a Catch

By Maxx Chatsko – Updated Nov 7, 2016 at 11:26AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

While gross margins are improving, nearly 82% of quarterly earnings per share was derived from an asset sale.

Image source: Getty Images. 

What happened

Shares of performance chemicals manufacturer Chemours Company (CC 1.05%) are receiving a boost of nearly 14% in morning trading after a strong quarterly earnings report. 

Chemours Company was created when DuPont completed the spinoff of its performance chemicals business in summer 2015. It's been a difficult journey since. Shares ended last year down nearly 75% from the first day they began trading. Then, after touching new lows in mid-February, shares have maintained a steady climb toward $20 per share. Today's move puts the stock close to all-time highs set during the first trading day after the spinoff was completed.

So what

Three segments drive operations: titanium technologies, fluoroproducts, and chemical solutions. Each struggled in the first half of 2016 compared to the same period of last year, but investors are seeing signs in third-quarter financial results that better days are ahead. Improving market conditions help, but it also appears that Chemours Company is executing against its internal transformation plan to boost margins and earnings.

Here are the important financial metrics for investors to consider:






$1.398 billion

$1.486 billion


Gross profit

$342 million

$264 million


Net income

$204 million

($29 million)


Earnings per share (EPS)




Data source: Chemour Company press release.

There are a few things for investors to consider. First, while revenue dropped year over year, improved margins resulted in higher gross profits. That's a good thing, because it shows signs of a healthier business.

Second, net income and EPS during the most recent quarter were substantially higher than the comparison period, but there's some fine print attached. Of the $204 million in net income, $169 million was derived from gains on an asset sale. That's equivalent to $0.92 of quarterly EPS. Earnings are earnings, but investors shouldn't expect the same performance every quarter. 

Now what

Chemours Company would have posted quarterly EPS of $0.19 even without the asset sale, which is markedly better than the year-ago results. Moreover, the company has posted EPS of $1.30 for the first nine months of 2016 (or EPS of $0.38 without the asset sale), compared to negative $0.02 for the same period last year. That hints that management's plan is working -- and receiving a boost from improving market conditions that are lifting both demand and average selling prices for the company's products. 

Still, investors will want to see consistent performance from the company before getting too excited. Chemours Company has witnessed shrinking revenue and profits in each of the last four years. One good quarter doesn't change that.

Maxx Chatsko has no position in any stocks mentioned. Follow him on Twitter to keep up with developments in engineered biology and materials science.

The Motley Fool has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.